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Pirect-Access Valve Replacement
Novel Approach for Off-Pump Valve Implantation Using Valved Stents
hristoph H. Huber, MD,* Lawrence H. Cohn, MD,* Ludwig K. von Segesser, MD†
oston, Massachusetts; and Lausanne, Switzerland
OBJECTIVES This study validates the off-pump antegrade transventricular route for ultrasound-guided
direct-access aortic valved stent implantation.
BACKGROUND Direct-access aortic valved stent implantation offers numerous advantages over the remote-
access percutaneous approach and may one day provide an alternative to surgical aortic valve
replacement.
METHODS Valved stents were implanted off-pump in 12 pigs (68.5.0  7.3 kg) via direct-access
transapical approach using a left-sided mini-thoracotomy and continuous ultrasonic and
fluoroscopic guidance. Acute valved stent function was studied with intravascular and
intracardiac ultrasound. All valved stents were tested in vitro before insertion. Macroscopic
analysis was performed at necropsy.
RESULTS In 8 of 12 pigs, valved stents were delivered to the target site over the native aortic valve
leaflets without interference of coronary blood flow and with good acute valve function. Two
valved stents were deployed and supra-annularly occluded the coronary orifice, leading to fatal
outcome. Two valved stents dislodged into the left ventricle, one because of size mismatch
and one that failed to unfold correctly.
CONCLUSIONS Twelve pigs underwent deployment of a valved stent in the aortic position. Six valves observed
for an average 4.5-h period showed satisfactory postimplantation valve function. (J Am Coll






























ahe clinical feasibility of percutaneous off-pump implanta-
ion of valved stents in the right and left heart has been
emonstrated (1). The remote access technique, however, is
ot suited to off-pump surgical aortic valve replacement
AVR) because the diseased aortic valve cannot removed by
his route, and it is preferable to remove heavily calcified
ative leaflets before implanting valved stents. More than a
ecade has passed since Andersen (2) published the princi-
le of valved stent implantation for transluminal aortic
lacement. Yet introducing valved stents into the aorta
emains a major experimental challenge without consensus
s to design, expansion method, access, direction of delivery,
r optimal deployment and positioning. We present a new
oncept for valved stent design and implantation using a
eft-sided mini-thoracotomy and direct-access–transapical
pproach, with the goal of developing an off-pump surgical
VR technique that might one day substitute for on-pump
VR.
ATIENTS AND METHODS
alved stent design and in vitro testing. The valved stent
ustom designed for this study (Fig. 1) is based on a
reviously described prototype (3). The outer scaffold is
onstructed of three linked nitinol Z-stents that form a
ylindrical structure with minimal surface coverage. The
elf-expanding characteristics of this valved stent eliminate
he need for balloon expansion. A low-profile tissue valve is
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005, accepted April 5, 2005.utured into the stent scaffold. Before implantation in vivo,
ll valved stents undergo static and dynamic (30 min)
erformance testing inside a pulsatile hydrodynamic mock
oop circuit equipped with a high-fidelity tip-mounted
illar pressure transducer. Acute valve function is moni-
ored in vivo with real-time intravascular ultrasound (IVUS)
12.5 MHz, 6-F) (Clearview, Boston Scientific Corpora-
ion, Sunnyvale, California). Criteria determining suitability
or implantation include transvalvular gradient 8 mm Hg
nd regurgitation value 1°.
nimal studies. Direct-access valved stent implantation
as performed in 12 pigs (68.5.0  7.3 kg). All animals
eceived humane care in compliance with the “Principles of
aboratory Animals” formulated by the National Society of
edical Research and the “Guide for the Care and Use of
aboratory Animals” prepared by the Institute of Labora-
ory Animal Resources and published by the National
nstitutes of Health. All data are expressed as mean  SD.
irect-access implantation technique. The jugular veins
nd carotid arteries are mobilized and animals fully
quipped for complete invasive monitoring. An 11-F intro-
ucer (B-Braun, Medical Inc., Bethlehem, Pennsylvania) is
nserted into the right femoral vein to provide intracardiac
ltrasound (AcuNav) access.
A 5- to 10-cm incision is made. The sixth intercostal
pace is entered. A xylocaine (1.5 mg/kg) drip is started to
inimize arrhythmias. Two purse-string sutures (Prolene
-0) are placed on the left ventricular (LV) apex using the
ative pericardial sac for reinforcement. After hepariniza-
ion (300 IU/kg), the 10-F AcuNav probe (Sequoia, oper-
ting frequencies 4.0 to 10.0 MHz, 90 cm insertion length,
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July 19, 2005:366–70 Direct-Access Percutaneous Valve Replacementerted into the right atrium (Fig. 2). Predeployment mea-
urements of the aortic valve, root, and coronary ostia
onfiguration are made with intracardiac ultrasound to avoid
ostdeployment interference caused by the echo-dense stent
truts, a major disadvantage of transesophageal echocardi-
graphy.
V valved stent implantation. The implant is hand-
rimped to the delivery device (Fig. 3). The LV apex is
unctured and a guide wire is inserted under fluoroscopic
uidance. An 8-F introducer (Arrows, Reading, Pennsylva-
ia) is advanced over the guide wire, which is placed
hrough the aortic valve into the descending aorta. Catheter
ocation is confirmed by AcuNav. The monorail wire-
uided disposable IVUS 6-F catheter transducer (Sonicath
ltra 6, 12.5MHz Imaging Catheter, Medi-tech, Water-
own, Massachusetts) is advanced for aortic road mapping.
he location of the IVUS probe is monitored with AcuNav
nd fluoroscopy for target site identification. Three to four
adiopaque markers are placed on the skin to provide
dditional fluoroscopic reference points at the level of the
ortic annulus, end of the native leaflet in systole, sinotu-
ular junction, and beginning of the brachiocephalic trunk.
he fluoroscopic C-arm and operating table are locked into
osition to avoid parallaxes.
cuNav and fluoroscopy for real-time valved stent de-
loyment monitoring. After removing the IVUS and 8-F
ntroducer, the valved stent delivery system is advanced over
he guide wire under fluoroscopic and AcuNav guidance.
hen fluoroscopic and sonographic target sites reach con-
ruency, the valved stent is deployed orthotopically over the
ative valve leaflets, releasing the distal end first. If the
ocation remains unchanged, the proximal end is released.
Abbreviations and Acronyms
AcuNav intracardiac ultrasound
AVR  aortic valve replacement
CBF  coronary blood flow
IVUS  intravascular ultrasound
LCA  left coronary artery
LV  left ventricle/ventricular
RCA  right coronary artery
RCSSI  residual coronary sinus stent indexFigure 1. Valved stent used for off-pump dhe valved stent is targeted to land slightly above the
ptimal site to ensure that the entire device can be pulled
ack if needed after opening the first line of the Z-stent.
he self-expanding nitinol stent has a low metal-to-stent
atio with minimal contact area between the interface of the
tent and aortic wall. These features increase the expansion
orce at the interface, creating a firm attachment to the
ortic root without injuring the aortic wall. This stent
esign is being used clinically for aortic endovascular
rocedures.
he residual coronary sinus stent index. We used the
esidual coronary sinus stent index (RCSSI) to evaluate
oronary blood flow (CBF) impairment. This index com-
ares the flow ratio between the native coronary flow and
he blood flow required to pass through the valved stent
fter implantation. More specifically, the RCSSI is a com-
arison between the coronary cross-sectional surface area
nd the plane defined by the valved stent and the native
ortic wall (Fig. 4). Coronary diameter was measured at the
ermination of the sinus portion. The residual stent aortic
all plane was measured at the level of the coronary orifice.
ll measurements were made using intracardiac ultrasound.
o calculate the index value, the distance of the stent from
he aortic wall (residual gap at the level of the aortic sinus
ortion) is divided by the coronary diameter. Coronary
igure 2. Navigating the valved stent through the heart with intracardiac
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Direct-Access Percutaneous Valve Replacement July 19, 2005:366–70lood flow impairment was not observed for index values
1.
utcome assessment. In vivo assessment included leaflet
otion, planimetric valve orifice, RCSSI, CBF, character-
stics of the left coronary artery (LCA), transvalvular gradi-
nt, regurgitation, and paravalvular leaking. After the ex-
eriments, animals were sacrificed and a macroscopic
nalysis was performed at necropsy.
ESULTS
n vitro study. All valved stents demonstrated good func-
ion, with a pressure gradient of 5.2  2.6 and mean flow
igure 3. Valved stent and delivery system: the off-pump valved stent was
ollapsed radially and then manually loaded into a standard endoprosthetic
elivery device with a maximum diameter of 9.2 mm.i
igure 4. Intracardiac ultrasound after orthotopic valved stent implanta-
ion. LCA  left coronary artery.ate of 4.7  1.5 l/min. Intravascular ultrasound imaging
xhibited full opening and closing of the pericardial leaflets
n all valves. Mild paravalvular leakage was observed in 2 of
2 valved stents. No valved stent migration occurred inside
he silicon valved stent chamber.
n vivo study. AcuNav measurements revealed aortic di-
meter 23.0 2.2 mm, valve area 3.76 1.3 cm2, height of
he native leaflets 11.4  2.4 mm, depth of the coronary
inuses of Valsalva 4.2  1.3 mm, height of the sinus
ortion 14.6  1.7 mm, and diameter at the sinotubular
unction 25.2  2.8 mm.
Eight of 12 implanted valved stents were delivered
ccurately. Two were deployed supra-annularly and oc-
luded the right coronary artery (RCA). Another two
islodged into the LV, one because of size mismatch, the
ther because of failure to fully deploy.
AcuNav demonstrated good leaflet motion, with full
alvular opening and closing in all correctly delivered,
eployed, and sized valved stents. The overall planimetric
alve orifice area was 2.6  0.8 cm2. Of the eight correctly
eployed valved stents, one had mild-to-moderate paraval-
ular leakage due to size mismatch and one exhibited mild
egurgitation. All eight valved stents had a low transvalvular
radient of 5.3  3.9 mm Hg (mean, peak-to-peak) on
nvasive measurement and 5.6 4.7 mm Hg on noninvasive
easurement.
Continuous cardiac output remained stable (5.2  0.6
/min valved stent. 4.7  0.4 l/min) for the eight correctly
elivered valved stents. Intracardiac color Doppler imaging
evealed laminar blood flow.
Procedure time was typically 120 min (range 90 to 180
in), and duration of delivery and deployment was 4 to 6
in. The postimplantation CBF pattern using AcuNav
olor Doppler and M-mode (Fig. 5) indicated no signs of
BF impairment in the valved stents deployed exactly on
arget. Residual coronary sinus stent index was obtained to
valuate potential flow impairment in the LCA (Fig. 5).
ean distance between the coronary orifice and aortic wall
as 8.1  2.4 mm. Mean diameter of the LCA was 5.7 
.2 mm, yielding an RCSSI value of 1.6  0.5. The
ostimplantation observation period was 4.5  1.8 h.
Postmortem examination (Fig. 6) confirmed that 8 of 12
alved stents were correctly positioned and firmly anchored
o the aortic wall. No implants showed signs of coronary
bstruction. Necropsy confirmed that the two supra-annular
eployments occluded the RCA. The two dislodged valved
tents were found in the LV. Macroscopic analysis provided
o evidence of damage to the aortic wall, signs of dissection,
r hematoma. Eight valved stents were structurally sound.
ll were thrombus-free.
ISCUSSION
his acute animal study confirms that antegrade direct-
ccess orthotopic aortic valve implantation via the LV apex
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July 19, 2005:366–70 Direct-Access Percutaneous Valve Replacementemote access percutaneous antegrade and retrograde valved
tent implantation in the pulmonary or aortic position in
elected patients (1,4,5). However, the remote access tech-
ique is not a viable alternative to surgical AVR. Innovative
urgical techniques are becoming increasingly less invasive
6). These innovations are likely to improve measurable
arameters such as patient outcome, length of hospital stay,
nd perioperative mortality and morbidity, but more data
re needed to establish their true benefits.
Development of an off-pump surgical AVR technique
egan in our laboratory in 1999 (3,7,8). Early experience
ith direct right ventricular access for antegrade pulmonary
alved stent implantation encouraged us to develop an
nalog for the left heart. The advantages of direct-access via
he LV apex include avoidance of the cardiopulmonary
irculation, decreased distance to the target site, and ability
o deliver larger devices for valve removal.
Figure 5. M-mode recordings showing stable left anterior descenigure 6. A valved stent in situ after antegrade off-pump implantation at necrops
lue catheter in the right coronary artery.Cribier et al. (1,4) demonstrated that the antegrade
pproach to aortic valved stent implantation was feasible.
owever, mitral valve function was compromised by the
ransvalvular guidewire, resulting in severe mitral regurgita-
ion in one-third of reported patients (1).
Design features for optimal implantation or replace-
ent of the aortic valve include: 1) antegrade access
hrough the LV apex; 2) a delivery system with direc-
ional guidance to eliminate the risk of coronary orifice
bstruction; and 3) a mechanism for reloading malposi-
ioned valved stents.
AcuNav in combination with fluoroscopy can locate the
evel of deployment with precision, but is not sufficient to
onitor rotation of the device within the aorta before
eployment. Currently, we are developing a radiopaque
arker for the delivery envelope that contains the collapsed
alved stent.
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Direct-Access Percutaneous Valve Replacement July 19, 2005:366–70Four of 12 valved stents were incorrectly placed at
ecropsy. Two were dislodged, one because of failure to
ully expand, attributed to difficulties in collapsing and
oading the device into the delivery system, and the other
ecause an undersized valved stent was used in a larger than
nticipated aortic root. Both animals remained stable during
he operation, but all attempts to recover or reposition the
evice without going on pump failed. Only one valved stent
islodged after it was initially correctly placed. Similar
ifficulties have been described (9). Two valved stents were
eployed supra-anularly and occluded the RCA.
No interference with CBF was found in correctly placed
nd deployed devices. Previous studies lack data on postim-
lantation CBF secondary to interference from echo-dense
tent struts. AcuNav eliminated much of this interference in
he present study, permitting reliable postimplantation CBF
nalysis. In line with previous reports (8), RCSSI was a
seful indicator for absence of CBF flow interference for all
ndex values 1. Moreover, leaving the native leaflets in
lace did not cause coronary ostia obstruction. These
ndings conflict with other published data (9), which
emonstrate a high failure rate with valved stent implants in
he annular aortic position (orthotopic) consequent to flow
estriction caused by the native leaflets.
Further measures to ensure the safety of valved stent
ortic valve implantation and replacement include the de-
elopment of embolic devices to protect the coronary
rifices and aortic arch, similar to the devices used for
ercutaneous carotid endarterectomy or the aortic filter
annulae used in cardiac surgery. Specialized tools for
emote decalcification and tissue removal are also needed.
everal have been proposed, such as laser ablation, ablation
hambers, or cutting catheters, but experimental data are
acking to support their feasibility. A temporary valve to
upport LV function during the removal/replacement inter-
al and to overcome increased afterload caused by embolic
lters and intra-aortic tools used for decalcification will also
e required. Previous publications have proposed valve-
ipped catheters as a temporary solution. Left ventricular
9ssist devices placed in the LV outflow tract, such as the
mpella VAD catheter, might also work.
The necessity of placing valved stents in patients with
eavily calcified aortic valves calls for new strategies and
echniques such as the proposed direct-access approach.
ur experimental data demonstrate that direct-access ante-
rade off-pump aortic valved stent implantation through the
V apex is feasible in animals with normal, noncalcified
eaflets. The absence of CBF impairment or mitral valve
indrance in properly placed and sized devices makes the
irect-access valved stent-based approach a promising new
echnology.
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5 Francis Street, Boston, Massachusetts 02115. E-mail:
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